| Title | Early COVID-19 XBB.1.5 vaccine effectiveness against hospitalisation among adults targeted for vaccination, VEBIS hospital network, Europe, October 2023–January 2024 / |
|---|---|
| Authors | Antunes, Liliana ; Mazagatos, Clara ; Martínez-Baz, Iván ; Naesens, Reinout ; Borg, Maria-Louise ; Petrović, Goranka ; Fatukasi, Terra ; Jančorienė, Ligita ; Machado, Ausenda ; Oroszi, Beatrix ; Husa, Petr ; Lazar, Mihaela ; Dürrwald, Ralf ; Howard, Jennifer ; Melo, Aryse ; Pérez-Gimeno, Gloria ; Castilla, Jesús ; Bernaert, Eva ; Džiugytė, Aušra ; Makarić, Zvjezdana Lovrić ; Fitzgerald, Margaret ; Mickienė, Auksė ; Gomez, Verónica ; Túri, Gergő ; Součková, Lenka ; Marin, Alexandru ; Tolksdorf, Kristin ; Nicolay, Nathalie ; Rose, Angela M. C |
| DOI | 10.1111/irv.13360 |
| Full Text |
|
| Is Part of | Influenza and other respiratory viruses.. Hoboken : Wiley. 2024, vol. 18, iss. 8, art. no. e13360, p. [1-7].. ISSN 1750-2640. eISSN 1750-2659 |
| Keywords [eng] | COVID-19 XBB.1.5 vaccine ; Europe ; SARS-CoV-2 hospitalisation ; vaccine effectiveness |
| Abstract [eng] | We conducted a multicentre test-negative case–control study covering the period from October 2023 to January 2024 among adult patients aged ≥ 18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between 69% at 14–29 days and 40% at 60–105 days post vaccination. The adapted XBB.1.5 COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5 months post vaccination, with VE > 70% in older adults (≥ 65 years) up to 1 month post vaccination. |
| Published | Hoboken : Wiley |
| Type | Journal article |
| Language | English |
| Publication date | 2024 |
| CC license |
|